Objective: No consensus exists regarding induction therapy for patients undergoing lung transplantation. Some studies have shown that administering induction agents could reduce the risk of acute rejection. This study analyzed differences in the acute rejection rate or outcomes between patients receiving and not receiving induction therapy.
Methods: This retrospective study included patients who underwent lung transplantation between 2006 and 2016. Patients who died within 14 days after lung
transplantation were excluded. Efficacy outcomes were the acute rejection rate within 1 and 12 months and the 1-year survival rate. Safety outcomes were changes in renal function and the occurrence of nosocomial or opportunistic infection within 1 year. Patients who received administered induction agents were included in the induction group, whereas those who did not receive administered induction agents were included in the non-induction group.
Results: A total of 43 patients underwent lung transplantation; however, 1 died after transplantation within 14 days. Of the remaining 42 patients, 6 and 36 were included in the induction and non-induction groups, respectively. One (16.7%) patient in the induction group and 21 (58.3%) patients in the non-induction group developed acute rejection within 1 month (p = 0.087). Furthermore, 4 (66.7%) patients in the induction group and 22 (75%) patients in the non-induction group developed acute rejection within 12 months (p = 0.664). The median time to rejection was 58 and 11 days in the induction and non-induction groups, respectively (p = 0.108). Neither the renal function nor infection rate significantly differed between the two groups.
Conclusions: Within 1 month, the acute rejection rate tended to decrease and the time to rejection tended to increase. However, no differences were noted in the survival rate, kidney function, or infection rate.
Summited for publication: 2021.2.5; Accepted for publication: 2021.5.24